NuCana (NASDAQ:NCNA) Downgraded by William Blair

NuCana (NASDAQ:NCNA) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, MarketBeat reports.

Separately, Oppenheimer reiterated an “outperform” rating and set a $150.00 price target on shares of NuCana in a research note on Monday, August 19th.

NuCana Stock Up 4.3 %

NuCana stock opened at $7.73 on Friday. The company has a market capitalization of $20.43 million, a P/E ratio of -0.66 and a beta of 0.99. The firm has a 50 day moving average price of $4.05 and a 200-day moving average price of $5.04. NuCana has a twelve month low of $2.53 and a twelve month high of $20.25.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NuCana stock. Glass Jacobson Investment Advisors llc acquired a new stake in shares of NuCana plc (NASDAQ:NCNA) during the second quarter, according to its most recent filing with the SEC. The fund acquired 15,000 shares of the company’s stock, valued at approximately $38,000. Glass Jacobson Investment Advisors llc owned 0.57% of NuCana as of its most recent filing with the SEC. 44.00% of the stock is owned by institutional investors.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.